The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (MITO CERV 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00997009
Recruitment Status : Active, not recruiting
First Posted : October 16, 2009
Last Update Posted : November 14, 2023
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute, Naples

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study aims to assess the activity of a combination of cetuximab (weekly) with carboplatin + paclitaxel (every three weeks) comparing it to chemotherapy alone in terms of event-free survival (EFS).

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: paclitaxel Drug: carboplatin Drug: cetuximab Phase 2

Detailed Description:
The poor long-term results in the standard treatment of chemotherapy for cervical cancer make research into new, more beneficial treatment strategies necessary. Cetuximab is a new type of drug that blocks the epidermal growth factor receptor (anti-EFGR), and has shown significant activity in other cancers (colon, head and neck) where expression of EGFR is high. Cervical cancer cells express EGFR in a very high proportion of cases, especially in recurrent or resistant disease. This study evaluates the activity of the addition of cetuximab to full doses of carboplatin and paclitaxel.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced and/or Recurrent Cervical Cancer
Study Start Date : October 2009
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A
chemotherapy plus cetuximab
 Drug: paclitaxel
175 mg/m2 IV day 1, every 21 days

Drug: carboplatin
AUC 5 IV day 1 every 21 days

Drug: cetuximab
400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
Active Comparator: Arm B
chemotherapy
 Drug: paclitaxel
175 mg/m2 IV day 1, every 21 days

Drug: carboplatin
AUC 5 IV day 1 every 21 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. event free survival [ Time Frame: after 3 and 6 cycles of treatment (each cycle is 21 days), and every 3 months thereafter up to 18 months ]

Secondary Outcome Measures :
  1. adverse events [ Time Frame: after each treatment cycle (each cycle is 21 days) up to 30days ]
    according CTCAE criteria

  2. overall survival [ Time Frame: 18 months ]
  3. skin toxicity and correlation with cetuximab activity [ Time Frame: after 3 and 6 cycles of therapy (each cycle is 21 days), and every 3 months thereafter up to 18 months ]
  4. EGFR/KRAS expression and correlation with cetuximab activity [ Time Frame: at 18 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced and/or metastatic cervical cancer patients untreated or having failed only one previous chemotherapy (with at least 6 months of progression free interval, with or without concomitant or sequential radiotherapy).
  • At baseline, presence of at least one measurable target lesion (a lesion that can be accurately measured in at least one dimension i.e. longest diameter at least 20 mm with conventional CT scan or at least 10 mm with spiral CT scan according to RECIST Criteria).
  • Not amenable to surgery and/or radiotherapy.
  • PS 0-1 according to ECOG.
  • Age >18.
  • Life expectancy of at least 3 months.

  • Adequate organ functions

    • Hematopoietic: Leukocytes > 3,000/mm3; Absolute neutrophil count > or = 1,500/mm3; Platelets count > or = 100,000/mm3; Hemoglobin > or = 9 g/dL

    • Hepatic: AST and ALT < or = 3 times upper limit of normal (ULN)*; Alkaline phosphatase < or = 3 times ULN*; Bilirubin < or = 1.5 times ULN

      *: < or = 5 times ULN if liver metastases are present

    • Renal: Creatinine clearance > or = 45 mL/min
  • No other invasive malignancy within the past 5 years except non-melanoma skin cancer.
  • All radiology studies must be performed within 28 days prior to randomization.
  • Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule.
  • Written informed consent.

Exclusion Criteria:

  • Pregnant (potentially fertile patients must use contraceptive measures to avoid pregnancy during and for at least 3 months after study participation and must have a negative serum pregnancy test at baseline).
  • Patients should not be breast-feeding during treatment and for 2 months following the end of treatment.
  • More than one previous chemotherapy line.
  • Active infection requiring antibiotics.
  • Symptomatic peripheral neuropathy >grade 2 according to the CTCAE.
  • Congestive heart failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.
  • Known hypersensitivity to the study drugs or to drugs with similar chemical structures.
  • Concurrent treatment with other experimental drugs.
  • Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997009


Locations
Layout table for location information
Italy
Ospedale Senatore Antonio Perrino
Brindisi, Italy
Ospedale Oncologico A. Businco
Cagliari, Italy
Universita Cattolica del Sacro Cuore
Campobasso, Italy
Istituto Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
Istituto Nazionale Tumori
Milano, Italy
A.O. Unversitaria Policlinico
Modena, Italy
Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico
Napoli, Italy, 80131
A.O. Universitaria Federico II
Napoli, Italy
Seconda Università di Napoli
Napoli, Italy
Istituto Oncologico Veneto
Padova, Italy
Ospedale Silvestrini
Perugia, Italy
Istituto Regina Elena
Roma, Italy
Universita Cattolica del Sacro Cuore
Roma, Italy
Ospedale S. Chiara
Trento, Italy
A.O. di Udine S. Maria della Misericordia
Udine, Italy
Sponsors and Collaborators
National Cancer Institute, Naples
Investigators
Layout table for investigator information
Principal Investigator: Sandro Pignata, M.D., Ph.D. National Cancer Institute, Naples
Principal Investigator: Francesco Perrone, M.D., Ph.D. National Cancer Institute, Naples
Principal Investigator: Alessandro Morabito, M.D., National Cancer Institute, Naples
Principal Investigator: Ciro Gallo, M.D., Ph.D. University of Campania "Luigi Vanvitelli"
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: National Cancer Institute, Naples
ClinicalTrials.gov Identifier: NCT00997009    
Other Study ID Numbers: MITO CERV 2
2009-010099-74 ( EudraCT Number )
First Posted: October 16, 2009    Key Record Dates
Last Update Posted: November 14, 2023
Last Verified: March 2023
Keywords provided by National Cancer Institute, Naples:
EGFR
chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
 Genital Diseases
Paclitaxel
Carboplatin
Cetuximab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological